

Market Outlook

The Nifty 50 started the week on a flat note, ended the session below 25000 after opening gap down near 24800. The India VIX ended at 14.04. The Advance-Decline Ratio is 0.42, indicating negative trend. On derivatives front Put OI has reduced at 24800 and added at 24900, while Call OI increased at 25000 indicates sideways trend. For coming session 25000 is key hurdle, where, 24800 is strong demand.

Key Indices Update

INDEX	CLOSE	CHANGE (%)
NIFTY	24971.90	-0.56
SENSEX	81896.79	-0.62
BANKNIFTY	56059.35	-0.34
INDIA VIX	14.04	2.74

Fills STATISTICS


Fills F&O Data

Sector	Buy/Sell	Change in OI
Index Futures	-1174.36	2.28%
Index Options	13646	2.41%
Stock Futures	-311.89	-2.05%
Stock Options	5019.79	1.11%

Fills & DII's Cash Segment (Rs. In Crore)

Category	Amount	MTD	YTD
FII	-1874.38	2127	16634
DII	5591.77	70534	166405

Fills Activity in Index Future



Amt in Crores


NIFTY 50 HIGH DELIVERY STOCKS

SYMBOL	DELIVERABLE QTY	CHG IN DLY RATIO VS PREV DAY	% CHG IN TRD QTY OVER PREV DAY
ETERNAL	10860709	-8.75	-57.13
ITC	10101657	-7.05	12.4
NTPC	4772017	-21.18	-50.11
INFY	4345407	-21.04	-13.68
POWERGRID	4304434	-15.56	-79.3
ICICIBANK	4193235	-4.31	-55.56
HDFCBANK	4136205	-9.98	-64.32
RELIANCE	3305165	-23.16	-79.36
HINDALCO	3210280	-17.78	-15.16
SBIN	2972352	-7.28	-51.18


NIFTY

Nifty	24993.00
OI (In contracts)	151372
CHANGE IN OI (%)	4.60
PRICE CHANGE (%)	-0.47
IMPLICATION	SHORT BUILDUP

NIFTY (CLOSE VS OI)



NIFTY OPTION CHAIN




Long Buildup

Symbol	Price	Price %	OI	OI %
CROMPTON	347	0.7	33625800	9.5
TORNTPHARM	3167	0.0	3117000	8.7
MARICO	695.35	0.3	19887600	8.3
BAJAJFINSV	1997.4	0.6	18113500	8.2
BHARTIARTL	1936	0.1	39592200	7.5


BANKNIFTY

Banknifty	56105.00
OI (In contracts)	59212
CHANGE IN OI (%)	1.44
PRICE CHANGE (%)	-0.34
IMPLICATION	SHORT BUILDUP

BANKNIFTY (CLOSE VS OI)



BANKNIFTY OPTION CHAIN



Short Buildup

Symbol	Price	Price %	OI	OI %
GODREJCP	1172.5	-1.3	9543000	19.1
AXISBANK	1216.4	-0.4	65720000	14.0
SUNPHARMA	1660.5	-0.4	17287550	10.8
RELIANCE	1455.5	-0.7	85690500	10.6
TVSMOTOR	2779.2	-1.4	9156700	9.4

Top 10 High PCR Ratio Stocks

SCRIP	PUT	CALL	P/C RATIO
MFSL	2955200	2252000	1.31
BEL	84533850	73176600	1.16
AUBANK	8913000	8200000	1.09
RBLBANK	11021050	10671450	1.03
FORTIS	1878600	1902625	0.99
MCX	3008650	3089900	0.97
CUMMINSIND	956700	1003600	0.95
ZYDUSLIFE	3351600	3596400	0.93
APLAPOLLO	1136800	1276100	0.89
KOTAKBANK	6587600	7512400	0.88

Top 10 Low PCR Ratio Stocks

SCRIP	PUT	CALL	P/C RATIO
SHREECEM	30000	140900	0.21
BOSCHLTD	34450	124350	0.28
PAGEIND	24660	80895	0.3
ONGC	31976700	100967400	0.32
SIEMENS	968325	2756050	0.35
GMRAIRPORT	29752875	79649550	0.37
TIINDIA	259800	696250	0.37
BAJAJ-AUTO	1747125	4582050	0.38
MAZDOCK	1673700	4397400	0.38
UNOMINDA	301950	796400	0.38

NIFTY 50 SUPPORT-RESISTANCE LEVELS

SYMBOL	R1	R2	PP	S1	S2
ADANIENT	2474	2494	2447	2427	2400
ADANIPORTS	1362	1373	1349	1338	1325
APOLLOHOSP	7092	7126	7039	7005	6953
ASIANPAINT	2293	2302	2282	2274	2263
AXISBANK	1227	1233	1221	1215	1210
BAJAJ-AUTO	8428	8495	8338	8271	8182
BAJAJFINSV	2001	2017	1984	1968	1951
BAJFINANCE	913	920	900	892	879
BEL	412	416	405	400	393
BHARTIARTL	1960	1986	1918	1892	1850
CIPLA	1511	1523	1498	1486	1473
COALINDIA	393	397	388	384	380
DRREDDY	1334	1340	1328	1321	1315
EICHERMOT	5550	5569	5520	5501	5471
ETERNAL	256	258	253	251	247
GRASIM	2735	2755	2714	2694	2673
HCLTECH	1748	1759	1728	1717	1697
HDFCBANK	1977	1989	1956	1944	1923
HDFCLIFE	786	794	774	766	754
HEROMO-TOCO	4391	4476	4280	4195	4084
HINDALCO	656	665	648	639	631
HINDUNILVR	2293	2305	2281	2270	2258
ICICIBANK	1438	1447	1425	1416	1403
INDUSINDBK	852	861	840	831	819
INFY	1631	1641	1621	1611	1600

SYMBOL	R1	R2	PP	S1	S2
ITC	420	422	418	417	415
JIOFIN	298	302	291	287	280
JSWSTEEL	1025	1042	1010	993	978
KOTAKBANK	2183	2196	2158	2145	2120
LT	3687	3711	3653	3628	3594
M&M	3219	3256	3156	3118	3055
MARUTI	12858	12915	12786	12729	12657
NESTLEIND	2414	2454	2367	2327	2281
NTPC	337	339	333	331	328
ONGC	253	255	251	250	248
POWERGRID	296	299	291	288	283
RELIANCE	1479	1493	1454	1440	1415
SBILIFE	1832	1854	1802	1780	1750
SBIN	804	811	795	788	778
SHRIRAMFIN	675	684	663	654	642
SUNPHARMA	1678	1689	1662	1652	1636
TATACONSUM	1106	1114	1095	1088	1076
TATAMOTORS	681	685	676	672	666
TATASTEEL	154	155	152	151	150
TCS	3452	3468	3431	3415	3395
TECHM	1714	1730	1687	1671	1644
TITAN	3557	3585	3525	3496	3464
TRENT	5972	6073	5843	5742	5614
ULTRACEMCO	11516	11590	11444	11370	11298
WIPRO	268	270	265	264	261

Disclaimer

Before you use this research report, please ensure to go through the disclosure inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 and Research Disclaimer at the following link: <https://www.religareonline.com/disclaimer>

Specific analyst(s) specific disclosure(s) inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 is/are as under:

Statements on ownership and material conflicts of interest, compensation– Research Analyst (RA) [Please note that only in case of multiple RAs, if in the event answers differ inter-se between the RAs, then RA specific answer with respect to questions under F(a) to F(j) below, are given separately]:

S. No.	Statement	Answer	
		Yes	No
	I/we or any of my/our relative has any financial interest in the subject company? [If answer is yes, nature of Interest is given below this table]		No
	I/we or any of my/our relatives, have actual/beneficial ownership of one percent. or more securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance?		No
	I/we or any of my/our relative, has any other material conflict of interest at the time of publication of the research report or at the time of public appearance?		No
	I/we have received any compensation from the subject company in the past twelve months?		No
	I/we have managed or co-managed public offering of securities for the subject company in the past twelve months?		No
	I/we have received any compensation for brokerage services from the subject company in the past twelve months?		No
	I/we have received any compensation for products or services other than brokerage services from the subject company in the past twelve months?		No
	I/we have received any compensation or other benefits from the subject company or third party in connection with the research report?		No
	I/we have served as an officer, director or employee of the subject company?		No
	I/we have been engaged in market making activity for the subject company?		No

Nature of Interest if answer to F(a) above is Yes:

..... Name(s) with Signature(s) of RA(s).

[Please note that only in case of multiple RAs and if the answers differ inter-se between the RAs, then RA specific answer with respect to questions under F(a) to F(j) above, are given below]

SS. No.	Name(s) of RA.	Signatures of RA	Serial Question of question which the signing RA needs to make a separate declaration / answer	Yes	No

Copyright in this document vests exclusively with RBL. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose, without prior written permission from RBL. We do not guarantee the integrity of any emails or attached files and are not responsible for any changes made to them by any other person.

No representations are being made about the performance or activities unless accompanied by data regarding performance, disclosures of all the risk factors, etc. and disclaimer that "Such representations are not indicative of future results

Name	Email ID	Designation
Vishvajeet Singh	vishvajeet.singh1@religare.com	Research Analyst